Sunitinib efficacy in reducing the aggressiveness of HER2-negative cells was confirmed in vivo, where it significantly slowed down tumor growth induced by cell injection of MamBo43HER2labile (Fig. 7B) and MamBo38HER2loss cells (Fig. 7C). Here, ERBB2 is linked to neoplasm.